Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Q-linea AB ( (SE:QLINEA) ) is now available.
Q-linea AB has announced a rights issue to raise approximately SEK 322 million, with strong support from existing shareholders and commitments covering about 85.6% of the issue. This funding aims to help the company reach break-even by 2027, accelerate commercialization, and strengthen its market position, particularly in the US market, where it anticipates significant growth.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea AB is a commercial company specializing in the development of instruments and consumables for infection diagnostics, particularly in vitro diagnostics. Its flagship product, the ASTar system, is a fully automated analysis tool for antibiotic susceptibility testing, aimed at improving treatment of bacterial infections such as sepsis. The company has received CE-IVD certification in Europe and FDA approval in the US, and is expanding its market presence globally.
Average Trading Volume: 18,969
Technical Sentiment Signal: Sell
Current Market Cap: SEK235.2M
For a thorough assessment of QLINEA stock, go to TipRanks’ Stock Analysis page.